These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 25409015)

  • 1. Design and development of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U
    PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.
    Comstedt P; Schüler W; Meinke A; Lundberg U
    PLoS One; 2017; 12(9):e0184357. PubMed ID: 28863166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and optimization of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Schlegl R; Lundberg U
    Vaccine; 2015 Nov; 33(44):5982-8. PubMed ID: 26277070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Protective Multivalent OspA Vaccine against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment.
    Nayak A; Schüler W; Seidel S; Gomez I; Meinke A; Comstedt P; Lundberg U
    Infect Immun; 2020 Mar; 88(4):. PubMed ID: 31932330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
    Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA
    PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
    Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
    J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
    Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
    Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.
    Izac JR; Oliver LD; Earnhart CG; Marconi RT
    Vaccine; 2017 May; 35(24):3178-3185. PubMed ID: 28479174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
    Scheckelhoff MR; Telford SR; Hu LT
    Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
    Klouwens MJ; Salverda MLM; Trentelman JJ; Ersoz JI; Wagemakers A; Gerritzen MJH; van der Ley PA; Hovius JW
    Vaccine; 2021 Apr; 39(18):2561-2567. PubMed ID: 33812741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii.
    Gern L; Hu CM; Voet P; Hauser P; Lobet Y
    Vaccine; 1997 Oct; 15(14):1551-7. PubMed ID: 9330467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development.
    Wilske B; Busch U; Fingerle V; Jauris-Heipke S; Preac Mursic V; Rössler D; Will G
    Infection; 1996; 24(2):208-12. PubMed ID: 8740124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
    Grosenbaugh DA; Rissi DR; Krimer PM
    Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
    Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
    J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
    Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
    Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice.
    Meirelles Richer L; Aroso M; Contente-Cuomo T; Ivanova L; Gomes-Solecki M
    Clin Vaccine Immunol; 2011 Nov; 18(11):1809-16. PubMed ID: 21918116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B.
    Fikrig E; Tao H; Chen M; Barthold SW; Flavell RA
    J Clin Invest; 1995 Oct; 96(4):1706-14. PubMed ID: 7560061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.